Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

2.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

3.

Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma.

van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA, Fleuren EDG.

Mol Cancer Ther. 2018 Jul;17(7):1365-1380. doi: 10.1158/1535-7163.MCT-17-1131. Review.

PMID:
29967215
4.

Systemic Treatment for Adults with Synovial Sarcoma.

Desar IME, Fleuren EDG, van der Graaf WTA.

Curr Treat Options Oncol. 2018 Mar 7;19(2):13. doi: 10.1007/s11864-018-0525-1. Review.

5.

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

van Erp AEM, Hillebrandt-Roeffen MHS, van Houdt L, Fleuren EDG, van der Graaf WTA, Versleijen-Jonkers YMH.

Target Oncol. 2017 Dec;12(6):815-826. doi: 10.1007/s11523-017-0528-z.

6.

ATR Is a Therapeutic Target in Synovial Sarcoma.

Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ.

Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16.

7.

Directing the use of DDR kinase inhibitors in cancer treatment.

Brandsma I, Fleuren EDG, Williamson CT, Lord CJ.

Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14. Review.

8.

Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes.

Fleuren EDG, Vlenterie M, van der Graaf WTA, Hillebrandt-Roeffen MHS, Blackburn J, Ma X, Chan H, Magias MC, van Erp A, van Houdt L, Cebeci SAS, van de Ven A, Flucke UE, Heyer EE, Thomas DM, Lord CJ, Marini KD, Vaghjiani V, Mercer TR, Cain JE, Wu J, Versleijen-Jonkers YMH, Daly RJ.

Cancer Res. 2017 Aug 15;77(16):4279-4292. doi: 10.1158/0008-5472.CAN-16-2550. Epub 2017 Jun 20.

9.

Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.

Vlenterie M, Hillebrandt-Roeffen MH, Schaars EW, Flucke UE, Fleuren ED, Navis AC, Leenders WP, Versleijen-Jonkers YM, van der Graaf WT.

Ann Surg Oncol. 2016 Sep;23(9):2745-52. doi: 10.1245/s10434-016-5341-x. Epub 2016 Jun 22.

10.

The kinome 'at large' in cancer.

Fleuren ED, Zhang L, Wu J, Daly RJ.

Nat Rev Cancer. 2016 Feb;16(2):83-98. doi: 10.1038/nrc.2015.18. Review.

PMID:
26822576
11.

The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.

Fleuren ED, Hillebrandt-Roeffen MH, Flucke UE, Te Loo DM, Boerman OC, van der Graaf WT, Versleijen-Jonkers YM.

Oncotarget. 2014 Dec 30;5(24):12753-68.

12.

Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.

Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, Franssen GM, Flucke UE, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT.

Int J Cancer. 2014 Dec 15;135(12):2770-82. doi: 10.1002/ijc.28933. Epub 2014 May 5.

13.

Theranostic applications of antibodies in oncology.

Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, Boerman OC.

Mol Oncol. 2014 Jun;8(4):799-812. doi: 10.1016/j.molonc.2014.03.010. Epub 2014 Mar 21. Review.

14.

Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.

Fleuren ED, Versleijen-Jonkers YM, Boerman OC, van der Graaf WT.

Biochim Biophys Acta. 2014 Apr;1845(2):266-76. doi: 10.1016/j.bbcan.2014.02.005. Epub 2014 Feb 28.

PMID:
24582852
15.

The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.

Fleuren ED, Versleijen-Jonkers YM, Heskamp S, Roeffen MH, Bouwman WH, Molkenboer-Kuenen JD, van Laarhoven HW, Oyen WJ, Boerman OC, van der Graaf WT.

Eur J Cancer. 2013 Sep;49(13):2851-8. doi: 10.1016/j.ejca.2013.04.009. Epub 2013 May 8.

PMID:
23664098
16.

Expression and clinical relevance of MET and ALK in Ewing sarcomas.

Fleuren ED, Roeffen MH, Leenders WP, Flucke UE, Vlenterie M, Schreuder HW, Boerman OC, van der Graaf WT, Versleijen-Jonkers YM.

Int J Cancer. 2013 Jul 15;133(2):427-36. doi: 10.1002/ijc.28047. Epub 2013 Feb 25.

17.

Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.

Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, Roeffen MH, van Laarhoven HW, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT.

Clin Cancer Res. 2011 Dec 15;17(24):7693-703. doi: 10.1158/1078-0432.CCR-11-1488. Epub 2011 Oct 28.

18.

Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development.

Fleuren ED, O'Toole S, Millar EK, McNeil C, Lopez-Knowles E, Boulghourjian A, Croucher DR, Schramek D, Brummer T, Penninger JM, Sutherland RL, Daly RJ.

Int J Cancer. 2010 Sep 1;127(6):1486-92. doi: 10.1002/ijc.25172.

19.

Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.

Brummer T, Larance M, Herrera Abreu MT, Lyons RJ, Timpson P, Emmerich CH, Fleuren ED, Lehrbach GM, Schramek D, Guilhaus M, James DE, Daly RJ.

EMBO J. 2008 Sep 3;27(17):2305-16.

Supplemental Content

Loading ...
Support Center